These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 30173328)

  • 21. Childhood Graves' ophthalmopathy: results of a European questionnaire study.
    Krassas GE; Segni M; Wiersinga WM
    Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired health-related quality of life in Graves' disease. A prospective study.
    Elberling TV; Rasmussen AK; Feldt-Rasmussen U; Hørding M; Perrild H; Waldemar G
    Eur J Endocrinol; 2004 Nov; 151(5):549-55. PubMed ID: 15538931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic recurrent stress due to panic disorder does not precipitate Graves' disease.
    Chiovato L; Marinò M; Perugi G; Fiore E; Montanelli L; Lapi P; Cavaliere R; Ciampi M; Patronelli A; Placidi G; Placidi GF; Cassano GB; Pinchera A
    J Endocrinol Invest; 1998 Dec; 21(11):758-64. PubMed ID: 9972676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life and neuropsychiatric disorders in patients with Graves' Orbitopathy: Current concepts.
    Bruscolini A; Sacchetti M; La Cava M; Nebbioso M; Iannitelli A; Quartini A; Lambiase A; Ralli M; de Virgilio A; Greco A
    Autoimmun Rev; 2018 Jul; 17(7):639-643. PubMed ID: 29729448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
    Edmunds MR; Boelaert K
    Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.
    Gunji K; De Bellis A; Kubota S; Swanson J; Wengrowicz S; Cochran B; Ackrell BA; Salvi M; Bellastella A; Bizzarro A; Sinisi AA; Wall JR
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1255-62. PubMed ID: 10199764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of quality of life in patients with Graves´ ophthalmopathy, before and after orbital decompression.
    Iacobæus L; Sahlin S
    Orbit; 2016 Jun; 35(3):121-5. PubMed ID: 27159575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing Graves' ophthalmopathy-specific quality of life in Korean patients.
    Choi YJ; Lim HT; Lee SJ; Lee SY; Yoon JS
    Eye (Lond); 2012 Apr; 26(4):544-51. PubMed ID: 22241019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.
    Khamisi S; Anders Karlsson F; Ljunggren Ö; Thulin M; Larsson A
    Cytokine; 2023 Sep; 169():156269. PubMed ID: 37307688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality of life in patients with Graves ophthalmopathy.
    Yeatts RP
    Trans Am Ophthalmol Soc; 2005; 103():368-411. PubMed ID: 17057811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
    Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
    Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretibial myxedema without ophthalmopathy: an initial presentation of Graves' disease.
    Lohiya S; Lohiya V; Stahl EJ
    Am J Med Sci; 2013 Jul; 346(1):73-5. PubMed ID: 23514670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperthyroidism in Patients with Graves' Ophthalmopathy, and Thyroidal, Skeletal and Eye Muscle Specific Type 2 Deiodinase Enzyme Activities.
    Molnár I; Szentmiklósi JA; Somogyiné-Vári É
    Exp Clin Endocrinol Diabetes; 2017 Sep; 125(8):514-521. PubMed ID: 28750432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Features of Graves' Ophthalmopathy and Impact of Enalapril on the Course of Mild Graves' Ophthalmopathy: A Pilot Study.
    Ataabadi G; Dabbaghmanesh MH; Owji N; Bakhshayeshkaram M; Montazeri-Najafabady N
    Endocr Metab Immune Disord Drug Targets; 2020; 20(1):139-148. PubMed ID: 31345156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measurement Properties of the Persian Translated Version of Graves Orbitopathy Quality of Life Questionnaire: A Validation Study.
    Kashkouli MB; Karimi N; Aghamirsalim M; Abtahi MB; Nojomi M; Shahrad-Bejestani H; Salehi M
    Ophthalmic Epidemiol; 2017 Feb; 24(1):3-10. PubMed ID: 28001456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of radioiodine therapy in hyperthyroidism (thyroid function, thyroid volume, Graves' ophtalmopathy, thyrotoxic heart disease).
    Ursu HI; Dumitriu L; Grigorie D; Simescu M; Vaida E; Belgun M; Popovici D
    Rom J Endocrinol; 1993; 31(3-4):155-63. PubMed ID: 7697064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality-of-Life Impairments Persist Six Months After Treatment of Graves' Hyperthyroidism and Toxic Nodular Goiter: A Prospective Cohort Study.
    Cramon P; Winther KH; Watt T; Bonnema SJ; Bjorner JB; Ekholm O; Groenvold M; Hegedüs L; Feldt-Rasmussen U; Rasmussen ÅK
    Thyroid; 2016 Aug; 26(8):1010-8. PubMed ID: 27370744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology.
    Villanueva R; Inzerillo AM; Tomer Y; Barbesino G; Meltzer M; Concepcion ES; Greenberg DA; MacLaren N; Sun ZS; Zhang DM; Tucci S; Davies TF
    Thyroid; 2000 Sep; 10(9):791-8. PubMed ID: 11041456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyrotropin receptor antibodies in hypothyroid Graves' disease.
    Kasagi K; Hidaka A; Nakamura H; Takeuchi R; Misaki T; Iida Y; Konishi J
    J Clin Endocrinol Metab; 1993 Feb; 76(2):504-8. PubMed ID: 8094394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.